Splitting four trials by clobazam use, seizures halved in 29.1% on cannabidiol against 15.7% without it, and in 52.9% against 27.8% among those already taking clobazam.
Nobody was randomised to clobazam — patients arrived on it or not — so the two groups differ in ways beyond the drug. The response was much higher in the clobazam group in both arms, placebo included, which the authors flag rather than resolve. Only Dravet and Lennox-Gastaut trials are pooled.
